Sertoli Treated Cord Blood for Spinal Cord Injury

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$150,000.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS050065-01
Award Id:
71826
Agency Tracking Number:
NS050065
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
3650 Spectrum Blvd., UTC II, Suite 170, TAMPA, FL, 33612
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
CYNDY DAVIS
(813) 866-6372
CDH@SANERON-CCEL.COM
Business Contact:
NICOLE KUZMIN-NICHOLS
(813) 866-6371
NKN@SANERON-CCEL.COM
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Stem cells from human umbilical cord blood (hUCB) represent a promising cellular therapeutic strategy for the treatment of cord injury (SCI). These cells are capable of differentiating into neurons and glia in vivo, engraft into specific sites of neurological injury, and produce recovery of function in rats following SCI. However, many cells die following cryopreservation, an essential processing step for storage of a cellular therapeutic product, and/or subsequently, following transplantation. The testis-derived Sertofi cells (SCs) and Sertoli cell conditioned media (SCM) have been shown to enhance the viability of cells post-thaw prior to transplantation, thereby increasing the likelihood of cell survival and therapeutic effect post-transplant. Treating the Hucb cells with SCM may provide the advantage that Saneron CCEL Therapeutics, Inc, is seeking in order to develop a marketable product for a cellular therapeutic treatment in SCI. The unknown is whether the optimal modification of hUBC utilizes rat- or human-based SCM. This Phase I research program is designed to define the optimal modification of hUBC processing and to determine the timing of SCM-treated hUCB cells that produces optimal behavioral recovery in an animal model of SCL The successful enhancement of cell viability, identification of the determinant factor of the enhancement, and the determination of the optimal timing of hUCB cells with SCM have important implications for the development of a cellular therapy for SCI and the therapeutic potential of stem cells in human cell transplantation.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government